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Influenza vaccine delivery and effectiveness in end-stage renal infectious disease is the second leading cause of death
disease. among ESRD patients and pulmonary infectious mortal-
Background. Influenza vaccination rates in the general pop- ity is tenfold higher in the ESRD population than in the
ulation have been associated with improved outcomes, yet general population [2]. Especially among the aged [3],high-risk populations, such as end-stage renal disease (ESRD)
and those with increased comorbidity [4], influenza vacci-patients, have received little attention in determining the po-
nation decreases the likelihood of hospitalization, mortal-tential benefits. This report assessed the frequency and effec-
tiveness of influenza vaccination, while also assessing disparit- ity, and costs [4–7]. A goal of the “Healthy People 2000”
ies in vaccination rates in the ESRD population. program was to immunize 60% of the elderly and other
Methods. Using the United States Renal Data System research high-risk individuals against influenza. For “Healthy Peo-
files containing claims for all Medicare ESRD patients, vaccina- ple 2010” the goal has been increased to 90% [8, 9].tion rates and outcomes among vaccinated and unvaccinated
Despite the recommendations for annual vaccination inpersons for the 1997 to 1998 and 1998 to 1999 influenza seasons
patients with ESRD [10], little is known about influenzawere compared after adjustment for baseline demographic fac-
tors and health characteristics. vaccination frequency and outcomes in this high risk
Results. Vaccination rates in the ESRD population were less population.
than 50% for each season. Influenza vaccination rates were lower The efficacy of influenza vaccination depends upon an
in non-whites, women, younger patients, and peritoneal dialysis intact B cell and T cell response, and studies have shownpatients. Influenza vaccination was associated with a lower risk
a decrease in both the number of B cells and the IgGfor hospitalization and death.
production among patients undergoing hemodialysisConclusions. Despite universal coverage of free influenza vac-
[11]. However, previous studies suggest that hemodialy-cination, the ESRD population had a less than 50% vaccination
rate for the years 1997 to 1998 and 1998 to 1999 as demonstrated sis patients’ response rates to influenza vaccination were
by Medicare billing data. Substantial differences were found similar to controls [12]. It is unclear whether uncertainty
in vaccination rates among non-whites and peritoneal dialysis about the benefits of influenza vaccination may lead to
patients. This study confirms that the ESRD populations bene-
a lower rate of influenza vaccination among patientsfit from influenza vaccination, suggesting that dialysis providers
with kidney failure. In addition, little is known regardingshould take advantage of all opportunities to immunize this
differences between hemodialysis and peritoneal dialysishigh-risk group.
patients in vaccination practices and effectiveness.
Thus, we undertook this study to determine the fre-
quency and outcomes associated with influenza vaccina-Influenza causes a significant burden of morbidity and
tion in this high-risk population. Influenza vaccinationmortality in the general population with an average of
rates and association of influenza vaccination with mor-20,000 deaths annually [1]. Patients with end-stage renal
bidity and mortality were determined in patients receiv-disease (ESRD) are likely at high risk for influenza infec-
ing either peritoneal dialysis or hemodialysis during twotion and complications given their altered immune status;
influenza seasons, 1997 to 1998 and 1998 to 1999, using
Medicare claims data.
Key words: influenza, vaccination, mortality and vaccination, hospital-
izations, immunization, peritoneal dialysis, hemodialysis.
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tients receiving dialysis in two influenza epidemic years: Hospitalization and mortality outcomes
1997 to 1998, and 1998 to 1999. The cohort of patients Principal discharge diagnoses for hospitalizations were
included in 1997 to 1998 consisted of patients who initi- examined to categorize cause of hospitalization. Hospi-
ated therapy for ESRD prior to October 1, 1996. The talization causes included in the analyses were any-cause,
October 1 date was chosen to ensure that complete data influenza/pneumonia (P&I; ICD-9-CM 480.xx-487.xx),
would be available for patients after January 1, 1997. bacteremia/viremia/septicemia (ICD-9-CM 038.xx, 790.7,
The period from January 1, 1997 through August 31, 790.8), and respiratory infection (ICD-9-CM 472.xx-474.0x,
1997 was used to characterize patient comorbidities. The 475.xx-477.9, 478.22-478.24, 480.xx-491.xx, 494, 510.x-
period from September 1 through December 31, 1997 511.x, 513.0, 518.6). CMS form 2746, the ESRD Death
was used to identify patients who received influenza vac- Notification form, was used to classify cause-specific mor-
cination, and then the period from January 1, 1998 tality. Three categories were created: cardiac (myocar-
through February 28, 1998 was used to assess hospitaliza- dial infarction, pericarditis, atherosclerotic heart disease,
tion and mortality [13]. Treatment modality (hemodialy- cardiomyopathy, cardiac arrhythmia, cardiac arrest, val-
sis or peritoneal dialysis) was determined on September vular heart disease, pulmonary edema), infection (septi-
1, 1997 and switching between renal replacement thera- cemia, pulmonary infection, viral infection, tuberculosis,
pies following this date was ignored. hepatitis B, other viral hepatitis, fungal peritonitis, other
The cohort for the subsequent influenza season epi- infections), and all other causes.
demic year initiated prior to October 1, 1997. The periods
for characterizing comorbidity and classifying influenza Statistical analysis
vaccination status were similar. The outcome assessment Baseline demographics and comorbid illness in vacci-
period for the 1998 to 1999 influenza season was January nated and unvaccinated persons were compared using
17, 1999 through March 20, 1999 [14]. The Centers for the Student t test and chi-square test. Unadjusted vacci-
Medicare and Medicaid Services (CMS) Medical Evi- nation rates were calculated overall and by age, gender,
dence Form 2728 was used to determine age, gender,
race, ethnicity, vintage (time on dialysis), diabetic status,
race, first ESRD service date, and cause of renal failure.
and mode of dialysis. The denominator included those
patients that initiated prior to October 1 of the previousVaccination status
year and survived to the beginning of the influenza sea-Billing codes were used to classify vaccination status
son examined. Chi-square tests were used to comparefrom the Medicare Part B Physician/supplier and Part
differences in vaccination rates between hemodialysisA hospital outpatient claims files that were searched for
and peritoneal dialysis patients. Influenza vaccinationCurrent Procedural Terminology (CPT) codes 90724,
rates were also adjusted using multiple logistic regression90657, 90658, 90659, or HCFA Common Procedure Cod-
models for age, gender, race, prior length of time withing System (HCPCS) G0008, during September 1 through
ESRD, and cause of renal failure (diabetes vs. other).December 31 of 1997 or September 1 through December
To determine the association between influenza vacci-31 of 1998 [15].
nation and the risk for hospitalization and mortality,
multiple logistic regression models were performed ad-Comorbidity index
justing for age, gender, race, ethnicity, ESRD network,A comorbidity index was calculated using the method
length of time with ESRD, cause of renal failure, Charl-of Charlson et al [16], which was later adapted for use
son comorbidity index and a severity of disease measurewith claims data by Deyo, Cherkin and Ciol [17]. The
of hospital days during the eight-month entry periodtime periods from January 1, through August 31 of 1997
from January 1, through August 31.or January 1, through August 31 of 1998 were used as
We hypothesized that the relationship between vacci-characterization periods, where Medicare Part A inpa-
nation and outcomes may be different at different agestient claims from these periods were searched for each
and with different degrees of comorbidity, since we rea-patient, and total hospital days for each patient were
soned that older, sicker patients might benefit more fromcalculated, as well as the total Charlson score. This score
influenza vaccination. In order to test this hypothesis,provides a single number as a measure of the overall
separate logistic models were performed by four agecomorbidity burden for that patient for inclusion in sub-
groups: 0 to 17, 18 to 39, 40 to 65, and greater than 65sequent analyses. All 10 ICD-9-CM diagnosis fields were
years old. We also performed separate multiple logisticsearched for codes as previously described in Deyo et al
regression models for patients with each comorbidity[17]. The total score for an individual was calculated as
included in the Charlson index. This was performed forthe sum of the weights accumulated during the eight-
both influenza seasons and for the outcomes of any-causemonth period. This comorbidity index has been applied
death, cause-specific death, death or hospitalization, andto ESRD populations previously and found to be strongly
associated with mortality and costs [19]. cause-specific hospitalization. We then looked for consis-
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Table 1. Patient characteristics and vaccination rates (September 1–December 31, 1998)
Hemodialysis, 112,409 (48.8%) Peritoneal dialysis, 13,091 (39.2%)
N (% vaccinated) % of Population % Vaccinated % of Population % Vaccinated P
Age
18 0.2 19.3a 1.7 14.2a NS
18–39 11.6 39.3 20.6 27.5 0.001d
40–64 43.1 46.2 48.8 36.3 0.001d
65 45.0 53.9 28.9 53.8 NS
Gender
Female 47.8 48.2a 50.8 38.1b 0.001d
Male 52.2 49.3 49.2 40.3 0.001d
Race
White 48.2 54.2a 61.6 44.3a 0.001d
Black 45.2 43.5 30.1 30.0 0.001d
Native American 1.9 45.9 1.8 25.3 0.001d
Asian 3.3 45.4 4.7 41.4 NS
Other 1.4 43.4 1.8 25.3 0.001d
Ethnicity
Hispanic 9.9 49.1c 10.3 30.5a 0.001d
Non-hispanic 90.1 48.8 89.7 40.1 0.001d
Prior ESRD time
1 year 2.3 49.8a 2.4 43.1a 0.005e
1–2 years 22.6 49.2 24.6 42.0 0.001d
2–4 years 32.2 50.7 35.2 40.3 0.001d
4 years 42.9 47.0 37.7 35.9 0.001d
Cause of renal failure
Diabetes 34.8 51.2a 27.8 42.4a 0.001d
Other 65.2 47.5 72.2 37.9 0.001d
NS is not significant.
a Statistical test of difference in vaccination rates 0.001, for example, the P value for a difference in vaccination rates by age, within HD, is less than 0.001
b Statistical test of difference in vaccination rates 0.01
c Not significant
d Statistical test of HD vaccination rate vs. PD vaccination rate, P  0.001
e Statistical test of HD vaccination rate vs. PD vaccination rate, P  0.05
tency of the size and sign of the parameter estimates for
vaccination across models. In order to test the generaliz-
ability of the impact of influenza vaccination, we per-
formed similar stratified multiple logistic regression anal-
yses by race (white, black, Native American, Asian,
other).
RESULTS
The hemodialysis and peritoneal dialysis population’s
combined vaccination rate was 47.8% in epidemic year
1998–1999. Patient characteristics and vaccination rates Fig. 1. Influenza vaccination rates for hemodialysis versus peritoneal
dialysis compared to the Health People 2000 and 2010 objectives infor that year are presented in Table 1 by dialysis mod-
the two cohorts. Symbols are: ( ) 1997 to 1998; () 1998 to 1999.
ality. The rate of vaccination among the 112,409 hemodi-
alysis patients was significantly greater (48.8%) than the
rate among the 13,091 peritoneal dialysis patients (39.2%).
This was true in virtually every demographic category. Figure 1 shows the adjusted vaccination rates for he-
Compared to hemodialysis, patients on peritoneal dial- modialysis and peritoneal dialysis patients, along with
ysis were younger, included a higher percentage of whites, Healthy People 2000 and Healthy People 2010 target
and had diabetes as a cause of renal failure less frequently. vaccination rates. Even after adjustment for age, gender,
Blacks were less likely to be immunized than whites, race, and ethnicity, the ESRD patients receiving perito-
especially among persons on peritoneal dialysis: 30.0% neal dialysis had significantly lower influenza vaccination
of blacks versus 44.3% of whites. Results for the 1997 rates compared to patients receiving hemodialysis (39.9
vs. 48.6% for 1998 to 1999, P  0.0001). Both groupsto 1998 epidemic year were similar, and are not shown.
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Table 2. Odds ratios for the impact of vaccinations on mortality and morbidity
Hemodialysis Peritoneal dialysis
1997–1998 1998–1999 1997–1998 1998–1999
Hospitalization
Any-cause 0.95 (0.92, 0.98) 0.93 (0.90, 0.95) 0.90 (0.83, 0.98) 1.01 (0.93, 1.11)
Influenza/pneumonia 0.88 (0.80, 0.97) 0.84 (0.77, 0.92) 0.95 (0.67, 1.37) 0.85 (0.59, 1.21)
Bacteremia/viremia/septicemia 0.83 (0.73, 0.94) 0.76 (0.67, 0.87) 0.48 (0.27, 0.86) 1.12 (0.62, 2.01)
Respiratory infection 0.93 (0.85, 1.01) 0.88 (0.81, 0.95) 0.88 (0.64, 1.21) 0.86 (0.62, 1.18)
Death
Any-cause 0.75 (0.71, 0.80) 0.77 (0.73, 0.81) 0.70 (0.59, 0.82) 0.83 (0.71, 0.97)
Cardiac 0.84 (0.77, 0.92) 0.82 (0.76, 0.88) 0.77 (0.61, 0.98) 0.90 (0.72, 1.13)
Infection 0.75 (0.64, 0.88) 0.64 (0.56, 0.72) 0.80 (0.56, 1.15) 0.85 (0.62, 1.17)
Other 0.69 (0.62, 0.75) 0.81 (0.75, 0.88) 0.58 (0.44, 0.78) 0.78 (0.61, 1.00)
Hospitalization or death 0.91 (0.89, 0.94) 0.89 (0.86, 0.91) 0.86 (0.79, 0.93) 0.96 (0.89, 1.05)
had substantially lower rates than the 2000 goal of 60% indicating a consistent effect of vaccination on outcomes
(data not shown).and the 2010 goal of 90%.
Table 2 displays odds ratios (vaccinated vs. not vacci-
nated) and 95% confidence intervals for overall and cause- DISCUSSION
specific hospitalization and mortality, for peritoneal dial-
This nationally representative study of influenza vacci-ysis and hemodialysis patients, for both influenza sea-
nation in both hemodialysis and peritoneal dialysis pa-sons, adjusted for age, gender, race, ethnicity, ESRD net-
tients provides new information regarding the vaccina-work, length of time with ESRD, cause of renal failure,
tion rates and effectiveness of this preventive health careCharlson comorbidity index and hospital days. Among
measure in this population. Overall, fewer than half ofhemodialysis patients, influenza vaccination was associ-
the patients received influenza vaccination. There was a
ated with a decreased risk of hospitalization for any cause,
demonstrated association of vaccination with a lower
P&I, and bacteremia/viremia/septicemia in both cohorts,
likelihood of death and hospitalization, which was more
and respiratory infection in the 1998 to 1999 cohort. consistent among hemodialysis patients.
Among peritoneal dialysis patients, only in the 1997 to The vaccination rate in the ESRD population falls well
1998 cohort were there statistically significant associa- below targets for the general population and is consistent
tions between influenza vaccination and hospitalization with influenza rates previously reported in the United
for any cause and bacteremia/viremia/septicemia, although States Renal Data System 2000 and 2001 Annual Data Re-
most of the other odds ratios were below one. Vaccina- port [20, 21], while vaccination rates have been climbing
tion was significantly associated with a decreased risk for in the general population [9]. The low rates of vaccina-
any-cause death and cause-specific death in hemodialysis tion among dialysis patients are difficult to explain, given
patients in both years. Among peritoneal dialysis pa- that cost and access to care, which are commonly thought
tients, vaccination was associated with a decreased risk to contribute to lower utilization of recommended medi-
for any-cause and other cause death for both years, with cal interventions, should not be an issue. This is despite
a decreased risk of cardiac death in the 1997 to 1998 co- the access to influenza vaccination without a co-payment
hort only, and not associated with infectious death. The and without meeting the annual deductible as part of
relationship between vaccination and the combined out- their Medicare benefits. The findings are even more strik-
come of any-cause hospitalization or death was statisti- ing since hemodialysis patients encounter the medical
cally significant for both cohorts of hemodialysis patients, system three times per week and peritoneal dialysis pa-
but only for the 1997 to 1998 cohort of peritoneal dialysis tients are generally seen every month by their dialysis
patients. Odds ratio estimates from the two influenza sea- providers. However, it may be that the lower rates of
sons were relatively consistent, except for the change in vaccination in the peritoneal dialysis population reflect
the direction of association noted for hospitalizations for the reduced frequency of medical encounters relative to
bacteremia/virema/septicemia among peritoneal dialysis the hemodialysis population. Other potential reasons for
patients: lower odds in the 1997 to 1998 cohort and higher low influenza vaccination rates that have been previously
odds (but not significant) for the 1998 to 1999 cohort. reported include: the subject did not know that it was
There were no consistent differences in the parameter needed, thought it caused the influenza, believed the shot
estimates of influenza vaccination in the analyses strati- could have adverse effects, did not think that it would
fied by age, comorbidity, and race in the outcomes of prevent the flu, and did not think about it [22]. The de-
sign of the current study precludes investigation of rea-death, hospitalization, and cause-specific hospitalization,
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eficial impact on cause-specific hospitalization, and thesons for low vaccination rates, and whether non-Medi-
consistency of results over the two influenza seasons.care dialysis patients receive influenza vaccinations more
Our findings are supported by numerous studies thator less frequently than Medicare patients. Previous stud-
have shown a protective effect of influenza vaccinationies have demonstrated improvements in influenza vacci-
against hospitalization for respiratory-related illnessesnation from 27 to 77% and corresponding decreases in
and other causes, including cardiopulmonary complica-hospital admissions for pneumonia (abstract, Steinman
tions [5, 33], a relationship shown in healthy populationset al, J Am Soc Nephrol 12:347A, 2001). A strategy for
as well as populations with chronic conditions. The re-improving vaccination rates may be to add this interven-
duction in mortality and hospitalization strongly supporttion to the CMS Clinical Performance Measures project
the recommendations that all dialysis patients shouldfor quality of care of the dialysis population. These ef-
receive this preventive health care measure.forts by CMS and others have been associated with im-
Several points should be considered when interpretingprovements in anemia management, dialysis adequacy,
our results. First, similar to any observational study, thereand increased utilization of simple fistulas [23].
may be baseline differences between the vaccinated andAlthough influenza vaccination has been recommended
unvaccinated that cannot be adjusted in a model of ob-for all ESRD patients, this report demonstrates marked
served differences. Although we cannot rule out a bias,disparities in vaccination rates, with non-whites less
the reductions in mortality and hospitalization from in-likely to receive influenza vaccination. This is consistent
fluenza vaccination are biologically plausible and thewith previously reported information on influenza vacci-
data were adjusted for important confounders such asnation among Medicare recipients over 65 and in other
age, race and comorbidity in our multiple logistic regres-populations [9, 24]. In addition, ESRD patients receiving
sion models. Second, only variables that were recordedperitoneal dialysis who were members of minority groups
in administrative databases were studied, and importantwere even less likely to be immunized against influenza
variables like tobacco use and socioeconomic status werethan minority group patients on hemodialysis. Of note,
unavailable. Third, the low vaccination rates may reflectour analyses did not show a difference in the benefits
a low sensitivity of billing data, or ambivalence to immu-of vaccination by racial group. Cost and access to care
nize on the part of patients and providers possibly relatedare not likely explanations for the discrepancy for the
to perceptions about lack of effectiveness in dialysis pa-reasons cited above. Some investigators have suggested
tients [34]. In a survey from a single network, facility-reasons for racial disparity in vaccination may include
reported influenza vaccination rates were 74.6%, com-limited access to primary care, failure of clinicians to
pared to rates of 40 to 50% from HCFA billing datavaccinate during health care visits, limited awareness
[35]. CMS billing data may underestimate the actual ratesamong minority patients of the need for vaccination, or
since some patients could receive vaccinations that aremisconceptions about the costs, adverse effects, risks,
not billed to Medicare, either because they are billed toand benefits of vaccination [25]. In addition, racial differ-
another primary payor or are not billed at all. However,ences have been reported for a variety of other medical
since the Rodgers study did not have a validation of theinterventions [26–28], and may relate to discriminatory
vaccination reports, it is difficult to interpret their resultspractices, ethnic variations in risk aversion and different
as the gold standard [35]. Moreover, assuming that the im-beliefs about treatment effectiveness that may influence
pact of vaccination would be in the same direction amongdecision making, and previous negative experiences with
those who received the vaccine but were not recorded inhealth care [29, 30]. The current study is unable to inves-
the data as such, then the significant findings of decreasedtigate reasons for these racial disparities.
hospitalizations and death reported herein may actuallyThis study shows the effectiveness of influenza vacci-
nation, particularly in the associated decreased mortality represent the minimum associations. In order to more
accurately quantify vaccination rates, and more preciselyrisk in both peritoneal dialysis and hemodialysis patients
and decreased rates of hospitalization among hemodialy- determine association with outcomes, primary data col-
lection is needed.sis patients. These findings agree with other studies that
have demonstrated that vaccination may improve sur- This study highlights the existence of a ready opportu-
nity to improve the care of patients on dialysis, and morevival among the elderly and chronically ill, and possibly
decrease costs [4–6]. In addition, influenza vaccination specifically, to focus attention on non-white and perito-
neal dialysis patients. To this end it appears that qualityhas been shown to decrease the likelihood of an acute
myocardial infarction [31], an important consideration improvement programs focused on influenza vaccination
rates are needed to address this vulnerable population.given the high risk for cardiac events in the ESRD popu-
lation [32]. Although we cannot demonstrate causality, The implementation of these programs could be expected
to have similar success as prior efforts focused on qualitythe likelihood of a true association of influenza vaccina-
tion with decreased mortality is strengthened by the ben- of dialysis and anemia care. Further monitoring of the di-
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